BioSpace News Archive

Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, announced that Karen Zaderej, chairman, CEO, and president will present at the Jefferies Virtual Healthcare Conference.

Only PARP Inhibitor to Improve Overall Survival vs. Enzalutamide or Abiraterone for Metastatic Castration-Resistant Prostate Cancer Patients with BRCA or ATM Mutations, A Key Secondary Endpoint in the Phase 3 PROfound Trial

Administration of AGTC’s proprietary adeno-associated virus (AAV) vectors expressing variants of the RPGR gene corrected early markers of disease and provided evidence of a rescue effect in an animal model of XLRP, with a favorable safety profile

Surface Oncology announced it has entered into a clinical trial collaboration with Merck, known as MSD outside the United States and Canada, through a subsidiary, to evaluate the safety and efficacy of combining Surface’s SRF617, an investigational antibody therapy targeting CD39, with Merck’s KEYTRUDA®, the first anti-PD-1 therapy approved in the United States.

Spring Bank Pharmaceuticals, Inc. announced that a trial in progress poster will be presented for the Phase 1a/1b trial of the company’s intravenously-administered STING agonist candidate, SB 11285, at the American Society of Clinical Oncology Annual Meeting, which will be conducted virtually from May 29-June 2, 2020.

Centene Corporation, which offers Medicare Advantage plans nationally through the WellCare and Allwell brands and locally through the Health Net brand, announced new efforts to help support its nearly 1 million Medicare Advantage members during the COVID-19 pandemic.

Nancy Wysenski, a Seasoned Pharmaceutical Executive with Rare Disease and Commercialization Experience, Appointed as a New Director

Used by more than 200 health systems for telehealth, platform goes beyond standard video conferencing to facilitate stethoscope audio, ECG live-streaming and FDA-cleared identification of atrial fibrillation ( AFib) and heart murmurs Patients can video chat with their providers and navigate self-operated stethoscope exams OAKLAND, Calif.--( BUSINESS WIRE )-- Eko today announced Eko Telehealth, the first and only AI-powered telehealth platfor

Only PARP inhibitor to improve overall survival vs enzalutamide or abiraterone in the biomarker-based subset of prostate cancer patients with BRCA1/2 or ATM mutations

Nemaura Medical, Inc. announced its 2020 Omnibus Incentive Plan was approved by shareholder vote at the Company’s Annual General Meeting on May 15, 2020.